Parker Institute shared on LinkedIn:
“Two companies founded by Parker Institute investigators, Azalea Therapeutics and Medici Therapeutics, have been named to Endpoints News’ 2026 Endpoints 11, which recognizes 11 of biotech’s most exciting startups shaping the future of the industry.
Azalea Therapeutics, co-founded by Justin Eyquem, of the University of California, San Francisco, is developing new approaches that meld gene editing and CAR-T.
Medici Therapeutics, co-founded by Ira Mellman, President of Research at the Parker Institute, is pursuing a highly personalized approach to cancer therapy.
Justin Eyquem and Ira Mellman
Congratulations to Justin, Ira and the teams at Azalea and Medici on this well-deserved recognition – and to the broader Parker investigator community for continuing to translate innovative cancer research into new possibilities for patients.”
Biotech’s most exciting startups of 2026: Meet this year’s Endpoints 11.
Other articles about Parker Institute on OncoDaily.